Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03405285
Other study ID # CoCath-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 28, 2018
Est. completion date June 30, 2018

Study information

Verified date July 2018
Source Spinal Singularity
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the safety and essential performance of the Connected Catheter System in males with neurogenic lower urinary tract dysfunction (NLUTD), both in an acute clinical setting, and during and extended period (up to 29 days) of home use.


Description:

The Connected Catheter (C2P) is a replaceable urinary prosthesis that is intended for use in male patients 18 years of age or older who have impaired bladder emptying due to neurogenic lower urinary tract dysfunction, and who are capable of operating the device in accordance with the provided instructions for use, or who have trained caregivers capable of doing the same. The device must be replaced every 29 days


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date June 30, 2018
Est. primary completion date June 30, 2018
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Males age = 18 with clinical diagnosis of neurogenic lower urinary tract dysfunction (NLUTD)

- Must be clinically suitable and capable of safely managing bladder using an intermittent voiding strategy Must have stable urinary management history with clean intermittent catheterization: no significant changes in bladder management regimen within past 12 months

OR:

Must have urodynamic profile suitable for CIC, as assessed via urodynamics study within past 12 months (including bladder capacity > 200mL without uninhibited bladder contractions)

- Subject's lower urinary tract anatomy (lengths of proximal and distal urethral must fall within the ranges serviceable by the Connected Catheter device, as specified in the investigational device instructions for use.

- For cases of NLUTD due to spinal cord injury, the subject must be in medically stable condition (i.e. post-spinal shock phase)

Exclusion Criteria:

- Active symptomatic urinary tract infection, as defined in this protocol (subjects may receive the CoCath Device after UTI has been treated)

- Significant risk profile or recent history of urethral stricture (e.g. stricture within past 90 days)

- Significant risk profile or recent history of clinically significant autonomic dysreflexia (e.g. History of hospitalization due to AD within past 12 months)

- Significant intermittent urinary incontinence (between catheterizations)

- Uninhibited bladder contractions and/or vesico-ureteral reflux that is not reliably controlled with medication or alternate therapy (e.g. botox injections)

- Pre-existing urinary pathologies and/or morphological abnormalities of the lower urinary tract or bladder (assessed during in-depth medical screening, including cystoscopy, urine analysis, and blood labs)

- Urinary tract inflammation or neoplasm

- Urinary fistula

- Bladder diverticulum (outpouching) > 5cm in size

- Chronic pyelonephritis (secondary to upper urinary tract infection(s) within past 6 months)

- Impaired kidney function or renal failure (assessed via blood creatinine levels > 2 mg/dL)

- Active gross hematuria

- Active urethritis

- Bladder stones

- Dependence on an electro-magnetic medical implant (e.g. cardiac pacemaker or implanted drug pump) or external device

- Individuals allergic or otherwise unable to take oral antibiotics

- Any physical or cognitive impairments that diminish the subject's ability to follow directions or otherwise safely use the CoCath System

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Connected Catheter
The Connected Catheter is a fully internal, urethral-indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The CoCath is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.

Locations

Country Name City State
United States West Coast Urology, 11411 Brookshire Avenue, Suite 508 Downey California
United States Tri Valley Urology, 25495 Medical Center Dr., Suite 204 Murrieta California

Sponsors (1)

Lead Sponsor Collaborator
Spinal Singularity

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Freedom from genito-urinary injury/trauma Improved bladder management without injury or trauma to genito-urinary tract 29 Days
Primary Successful Acute Performance- I To evaluate successful retention of Connected Catheter and Void On the day of Connected Catheter Insertion
Primary Successful Acute Performance -II To evaluate successful bladder voiding with Connected Catheter On the day of Connected Catheter Insertion
Primary Successful Acute Performance- III To evaluate successful removal of Connected Catheter On the day of Connected Catheter Insertion
Primary Successful Acute Performance- IV To evaluate successful post-void sealing of Connected Catheter Valve On the day of Connected Catheter Insertion
Primary Successful Home-Use Performance Successful Home-Use using same measures as Acute Performance 29 days
See also
  Status Clinical Trial Phase
Recruiting NCT05141487 - Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder
Completed NCT01920243 - Evaluation of a Bowel and Bladder Health Management Program for Individuals With Spinal Cord Injury (SCI) N/A
Completed NCT04528784 - Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis N/A
Enrolling by invitation NCT03336424 - Urinary Disorders in Patients With Multiple Sclerosis: Invasive Vs Non-invasive Investigations. N/A
Not yet recruiting NCT05075642 - Multicenter Observational Study for the Evaluation in Clinical Practice of Urinary Disorders in Multiple Sclerosis
Completed NCT02600715 - Reduction of Bladder Injection Pain With Belladonna Opiate Suppository Phase 4
Recruiting NCT04128709 - Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use N/A
Enrolling by invitation NCT05740527 - Ambulatory Closed-loop Stimulation for Bladder Control N/A
Completed NCT02501928 - Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity. Phase 3
Recruiting NCT06336304 - NXT Post-Market Clinical Follow-up
Completed NCT06445426 - Cystometry Using a Novel Microsensor System in Patients With Neurogenic Bladder Dysfunction
Recruiting NCT04819360 - Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis Phase 4
Terminated NCT02044510 - Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients Phase 2/Phase 3
Completed NCT01557244 - A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition Phase 3
Recruiting NCT05380661 - Heart Rate Variability and Anxiety During Urinary Bladder Catheterization N/A
Recruiting NCT04193709 - Recovery of Bladder and Sexual Function After Human Spinal Cord Injury N/A
Completed NCT02582151 - Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder N/A
Active, not recruiting NCT05232253 - Cystoealstometer (Bladder Monitor Device)-Home Use N/A
Completed NCT02673047 - Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder N/A
Completed NCT01773213 - Detrusor Contraction During the Ice-water-test N/A